GlassScriptPhysician profile
Ryan Lane Asher
NPI 1124435235
$3,068.54
in general payments reported to CMS, 2019-2025
24 companies · $639 in 2025
The $639 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $699 · 2023: $961 · 2024: $770 · 2025: $639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,369.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $504.68 | 2022-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Lilly USA, LLC | $357.21 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $323.01 | 2022-2025 | |
| Pfizer INC. | $255.59 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $249.04 | 2022-2025 | Farxiga, Fasenra |
| Otsuka America Pharmaceutical, INC. | $211.17 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $182.02 | 2022-2024 | |
| Abbott Laboratories | $176.33 | 2022-2023 | Freestyle Libre 2, Freestyle Libre 3, Freestyle Libre |
| Exact Sciences Corporation | $140.59 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Mylan Specialty L.P. | $124.98 | 2022 | |
| Janssen Pharmaceuticals, INC | $120.63 | 2024 | Xarelto |
| Novo Nordisk INC | $98.74 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Vertex Pharmaceuticals Incorporated | $69.68 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $59.56 | 2024 | Voquezna |
| Amgen INC. | $30.82 | 2024-2025 | Evenity, Repatha, Otezla |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $25.88 | 2022 | |
| Argenx US, INC. | $20.42 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $20.02 | 2025 | |
| Lundbeck LLC | $18.88 | 2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $18.62 | 2025 | Austedo Xr |
| Acadia Pharmaceuticals INC | $16.76 | 2025 | Nuplazid |
| Axonics, INC. | $15.62 | 2022 | |
| Abbvie INC. | $14.57 | 2025 | |
| Glaxosmithkline, LLC. | $13.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Asher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.